(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 October 2008 (23.10.2008)

PCT

(10) International Publication Number
WO 2008/127271 A3

(51) International Patent Classification:
C12P 21/08 (2006.01) *C07H 21/00* (2006.01)

(21) International Application Number:
PCT/US2007/019660

(22) International Filing Date:
7 September 2007 (07.09.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/843,249 8 September 2006 (08.09.2006) US

(71) Applicant *(for all designated States except US)*: **ABBOTT LABORATORIES** [US/US]; 100 Abbott Park Road, Abbott Park, IL 60064 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **WU, Chengbin** [CN/US]; 386 Prospect Street, Shrewsbury, MA 01545 (US). **DIXON, Richard, W.** [US/US]; 19 Nottingham Drive, Jefferson, MA 01522 (US). **BELK, Jonathan, P.** [US/US]; 89 Beaman Road, Sterling, MA 01564 (US). **YING, Hua** [US/US]; 15 Tyler Drive, Holden, MA 01520 (US). **ARGIRIADI, Maria, A.** [US/US]; 273 Main Street, Wayland, MA 01778 (US). **CUFF, Carolyn, A.** [US/US]; 23 Elliot Trail, Grafton, MA 01519 (US). **HINTON, Paul, R.** [US/US]; 321 Dunsmuir Terrace #4, Sunnyvale, CA 94085 (US). **KUMAR, Shankar** [US/US]; 3930 Kral Place, Pleasanton, CA 94588 (US). **MELIM, Terry, L.** [US/US]; 16b Sunnyside Lane, Derry, NH 03038 (US). **CHEN, Yan** [CN/US]; 4861 Central Avenue, Apt. 201, Fremont, CA 94536 (US).

(74) Agents: **SESHADRI, Tara** et al.; Abbott Bioresearch Center, 100 Research Drive, Worcester, MA 01605-4314 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

(88) Date of publication of the international search report:
9 April 2009

(54) Title: INTERLEUKIN -13 BINDING PROTEINS

(57) Abstract: The present invention encompasses IL- 13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hlL-13 activity, e.g., in a human subject suffering from a disorder in which hTL-13 activity is detrimental.

WO 2008/127271 A3